文献速递神经免疫

髓鞘少突胶质细胞糖蛋白抗体相关疾病的MRI特征综述

MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review.
PubMed 文献 · JAMA Neurol · 2026-09-28

该综述总结了MOGAD在视神经、脑和脊髓的典型MRI特征,强调其与MS及AQP4+NMOSD的鉴别要点,并推荐急性发作期标准化MRI协议。文章指出MOGAD影像病灶常可完全消退、放射学滞后常见,无症状影像活动罕见,提示监测MRI价值低于MS。

要点

  • MOGAD病灶常呈T2高信号且可完全消退,与MS持续病灶不同。
  • 推荐急性发作期采用标准化MRI协议,并审慎评估起病后重新基线化时机。
  • 识别提示替代诊断的影像红旗征有助于避免误诊。

核心结论

  • MRI是MOGAD评估的核心,识别其特征性影像表现和病灶动态有助于诊断。
  • 应用标准化MRI协议可优化临床实践并促进研究间 harmonization。

研究设计与样本

  • 本文为综述,汇总MOGAD视神经、脑和脊髓受累的典型MRI特征及2023诊断标准中的关键发现。

主要发现

  • MOGAD特征性影像演变包括放射学滞后、急性发作期病灶动态变化及T2病灶频繁消退。
  • MOGAD临床和影像均表现为发作相关神经炎症,无症状放射学活动罕见。
  • 综述总结了MOGAD与MS及AQP4+NMOSD鉴别的MRI特征并指出提示替代诊断的影像红旗征。

关键数值与推荐

  • 2023 MOGAD诊断标准将MRI作为确认发作、定义病灶分布和排除替代诊断的关键组成部分。

临床怎么用

  • 临床应使用推荐的急性发作期MRI协议,并理解重新基线化MRI的时机与效用。
  • 因无症状影像活动罕见,监测MRI在MOGAD中的临床效用低于MS。
  • 识别影像红旗征以排除替代诊断,避免延误诊断和不恰当治疗。

局限性

  • 原文未报告系统检索范围、纳入研究数量或证据等级等综述方法学细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion distribution, and excluding alternative diagnoses and is a key component of the 2023 MOGAD diagnostic criteria. However, its imaging spectrum and lesion evolution remain underrecognized in practice, and variability in imaging parameters can contribute to delayed diagnosis and suboptimal treatment. OBSERVATIONS: This article summarizes the hallmark MRI features of optic nerve, brain, and spinal cord involvement in MOGAD, including key findings from the 2023 diagnostic criteria, supported by illustrative figures and detailed tables. The characteristic evolution of MRI abnormalities in MOGAD is highlighted, including radiologic lag, lesion dynamics during acute attacks, and frequent T2-lesion resolution, contrasting with the persistent lesions typical of MS. A recommended MRI protocol for acute attacks is proposed, and the timing and utility of rebaselining MRI (ie, repeating the MRI to establish a new baseline) after onset are reviewed. The clinical course of MOGAD is of attack-related neuroinflammation evident clinically and radiologically, and asymptomatic radiological activity is rare, suggesting that surveillance MRI has less clinical utility than in MS and less value as a surrogate biomarker in clinical trials. MRI features that differentiate MOGAD from MS and AQP4+NMOSD are summarized and imaging red flags suggestive of alternative diagnoses are highlighted. Finally, emerging advanced imaging, artificial intelligence in MOGAD imaging, and the link between imaging and immunopathogenesis are reviewed. CONCLUSIONS AND RELEVANCE: MRI is central to MOGAD evaluation, and recognition of the characteristic imaging features and lesion dynamics outlined in this review can aid diagnosis. Application of the standardized MRI protocol summarized here can optimize use in clinical practice and promote harmonization across research studies. Future imaging and artificial intelligence applications may improve diagnosis, disease monitoring, and understanding of MOGAD pathogenesis.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Flanagan EP, Banwell BL, Cacciaguerra L, et al. MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review. JAMA Neurol. 2026. PMID: 42804180. doi:10.1001/jamaneurol.2026.3196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。